Product list
Kemex Pharma Products
60 products with active ingredients, strengths, pack sizes and therapeutic uses. Search or filter the list below.
Showing 60 of 60 products
| Enquire | ||||||
|---|---|---|---|---|---|---|
| 1 | AzacitidineInjectable | Azacitidine | 100 mg | Lyophilized for injection; vial × 1 | Myelodysplastic syndromes (MDS); acute myeloid leukemia (AML) | Enquire |
| 2 | BendamustineInjectable | Bendamustine | 25–100 mg | Injection; strength/presentation varies | Chronic lymphocytic leukemia; indolent B-cell non-Hodgkin lymphoma | Enquire |
| 3 | BleomycinInjectable | Bleomycin | 15 IU | Lyophilized for injection; vial × 1 | Hodgkin lymphoma; testicular cancer; selected squamous cell carcinomas; malignant pleural effusion | Enquire |
| 4 | CarmustineInjectable | Carmustine | 100 mg | Lyophilized for injection; vial × 1 + diluent | Brain tumors; multiple myeloma; conditioning regimens | Enquire |
| 5 | BusulfanInjectable | Busulfan | 60 mg | Concentrate for solution for infusion; vial × 8 | Conditioning before hematopoietic stem-cell transplantation | Enquire |
| 6 | CytarabineInjectable | Cytarabine | 1000 mg | Lyophilized for injection; vial × 1 | Acute myeloid leukemia; acute lymphoblastic leukemia; other hematologic malignancies | Enquire |
| 7 | CtarabineInjectable | Cytarabine | 100 mg | Lyophilized for injection; vial × 1 | Acute myeloid leukemia; acute lymphoblastic leukemia; other hematologic malignancies | Enquire |
| 8 | DacarbazineInjectable | Dacarbazine | 200 mg | Lyophilized for injection; vial × 1 | Metastatic melanoma; Hodgkin lymphoma | Enquire |
| 9 | DaunorubicinInjectable | Daunorubicin | 20 mg | Lyophilized for injection; vial × 1 | Acute myeloid leukemia; acute lymphoblastic leukemia | Enquire |
| 10 | EpirubicinInjectable | Epirubicin | 50 mg | Lyophilized for injection; vial × 1 | Breast cancer; selected lymphomas and solid tumors | Enquire |
| 11 | EtoposideInjectable | Etoposide | 100 mg | Solution for injection; vial × 1 | Small-cell lung cancer; testicular cancer; lymphomas and other malignancies | Enquire |
| 12 | MelphalanInjectable | Melphalan | 50 mg | Lyophilized for injection; vial × 1 + diluent | Multiple myeloma; conditioning before stem-cell transplantation | Enquire |
| 13 | IdarubicinInjectable | Idarubicin | 5–10 mg | Lyophilized for injection; vial × 1 | Acute myeloid leukemia; selected acute leukemias | Enquire |
| 14 | MitomycinInjectable | Mitomycin C | 5–20 mg | Lyophilized for injection; vial × 1 | Bladder cancer; gastrointestinal and other solid tumors | Enquire |
| 15 | TopotecanInjectable | Topotecan | 4 mg | Lyophilized for injection; vial × 1 | Ovarian cancer; small-cell lung cancer; cervical cancer | Enquire |
| 16 | VinblastineInjectable | Vinblastine | 10 mg | Lyophilized for injection; vial × 1 | Hodgkin lymphoma; non-Hodgkin lymphoma; testicular cancer and other malignancies | Enquire |
| 17 | VincristineInjectable | Vincristine | 1 mg | Lyophilized for injection; vial × 1 | Acute lymphoblastic leukemia; lymphomas; selected pediatric and other cancers | Enquire |
| 18 | VinorelbineInjectable | Vinorelbine | 10 mg/mL; 50 mg/5 mL | Solution for injection; vial × 1 | Non-small-cell lung cancer; metastatic breast cancer | Enquire |
| 19 | CarboplatinInjectable | Carboplatin | 150–450 mg | Lyophilized for injection; vial × 1 | Ovarian cancer; lung cancer; other solid tumors | Enquire |
| 20 | CyclophosphamideInjectable | Cyclophosphamide | 1000 mg | Lyophilized for injection; vial × 1 | Lymphomas; leukemias; breast cancer; ovarian cancer; conditioning regimens | Enquire |
| 21 | DocetaxelInjectable | Docetaxel | 80 mg | Solution for injection; vial × 1 + diluent | Breast cancer; prostate cancer; non-small-cell lung cancer; gastric/head and neck cancers | Enquire |
| 22 | DoxorubicinInjectable | Doxorubicin | 50 mg | Lyophilized for injection; vial × 1 | Breast cancer; lymphomas; sarcomas; leukemias; multiple solid tumors | Enquire |
| 23 | DoxorubicinInjectable | Doxorubicin | 20 mg | Lyophilized for injection; vial × 1 | Breast cancer; lymphomas; sarcomas; leukemias; multiple solid tumors | Enquire |
| 24 | FludarabineInjectable | Fludarabine | 50 mg | Lyophilized for injection; vial × 1 | Chronic lymphocytic leukemia; selected B-cell malignancies | Enquire |
| 25 | FluorouracilInjectable | Fluorouracil | 500 mg/10 mL | Solution for injection; vial × 5 | Colorectal, gastric, pancreatic, breast, head and neck and other cancers | Enquire |
| 26 | IfosfamideInjectable | Ifosfamide | 1 g | Lyophilized for injection | Soft-tissue sarcoma; testicular cancer; other solid tumors | Enquire |
| 27 | FulvestrantInjectable | Fulvestrant | 250 mg | Solution for injection; vial × 2 | Hormone receptor-positive, HER2-negative advanced/metastatic breast cancer | Enquire |
| 28 | LeucovorinInjectable | Leucovorin (folinic acid) | 50 mg | Lyophilized for injection; vial × 1 | Rescue after high-dose methotrexate; enhancement of fluorouracil therapy; methotrexate toxicity | Enquire |
| 29 | Liposomal DoxorubicinInjectable | Pegylated liposomal doxorubicin | 2 mg/mL* | Liposomal dispersion for injection; vial × 1 | Ovarian cancer; AIDS-related Kaposi sarcoma; multiple myeloma | Enquire |
| 30 | MesnaInjectable | Mesna | 400 mg | Solution for injection; vial × 1 | Prevention of urothelial toxicity from ifosfamide and selected oxazaphosphorines | Enquire |
| 31 | MethotrexateInjectable | Methotrexate | 50–500 mg | Lyophilized for injection; vial × 1 | Leukemias; lymphomas; osteosarcoma; breast and other cancers | Enquire |
| 32 | MethotrexateInjectable | Methotrexate | 50–500 mg | Solution for injection; vial × 1 | Leukemias; lymphomas; osteosarcoma; breast and other cancers | Enquire |
| 33 | MitoxantroneInjectable | Mitoxantrone | 2 mg/mL | Solution for injection; vial × 1 | Acute myeloid leukemia; prostate cancer; other hematologic malignancies | Enquire |
| 34 | OxaliplatinInjectable | Oxaliplatin | 100 mg | Lyophilized for injection; vial × 1 | Colorectal cancer; adjuvant and metastatic settings | Enquire |
| 35 | OxaliplatinInjectable | Oxaliplatin | 200 mg | Lyophilized for injection; vial × 1 | Colorectal cancer; adjuvant and metastatic settings | Enquire |
| 36 | PaclitaxelInjectable | Paclitaxel | 30, 100, 150, 300 mg | Solution for injection; vial × 1 | Ovarian, breast and non-small-cell lung cancers; other solid tumors | Enquire |
| 37 | DasatinibOral | Dasatinib | 20, 50, 70, 100 mg | Coated tablets × 60 | Philadelphia chromosome-positive chronic myeloid leukemia; Ph+ acute lymphoblastic leukemia | Enquire |
| 38 | HydroxyureaOral | Hydroxyurea | 500 mg | Hard capsules × 100 | Sickle cell disease; chronic myeloid leukemia and other myeloproliferative disorders | Enquire |
| 39 | GemcitabineInjectable | Gemcitabine | 200–1000 mg | Lyophilized for injection; vial × 1 | Pancreatic, breast, ovarian and non-small-cell lung cancers; bladder cancer | Enquire |
| 40 | AbirateroneOral | Abiraterone acetate | 250 mg | Coated tablets × 120 | Metastatic prostate cancer | Enquire |
| 41 | TemozolomideOral | Temozolomide | 5, 20, 100, 140, 180, 250 mg | Hard capsules × 5 / × 21 | Glioblastoma; anaplastic astrocytoma | Enquire |
| 42 | PalbociclibOral | Palbociclib | 75, 100, 125 mg | Hard capsules × 21 | HR-positive/HER2-negative advanced or metastatic breast cancer | Enquire |
| 43 | EnzalutamideOral | Enzalutamide | 40 mg | Hard capsules × 120 | Metastatic and non-metastatic castration-resistant prostate cancer; hormone-sensitive metastatic prostate cancer | Enquire |
| 44 | GefitinibOral | Gefitinib | 250 mg | Coated tablets × 30 | EGFR-mutated non-small-cell lung cancer | Enquire |
| 45 | LetrozoleOral | Letrozole | 2.5 mg | Coated tablets × 30 | Hormone receptor-positive breast cancer | Enquire |
| 46 | PomalidomideOral | Pomalidomide | 1, 2, 3, 4 mg | Hard capsules × 21 | Multiple myeloma after prior therapies; selected Kaposi sarcoma indication | Enquire |
| 47 | LenalidomideOral | Lenalidomide | 5, 10, 15, 25 mg | Hard capsules × 21 | Multiple myeloma; myelodysplastic syndromes with 5q deletion; mantle cell lymphoma in selected settings | Enquire |
| 48 | ImatinibOral | Imatinib | 400 mg | Coated tablets × 30 | Philadelphia chromosome-positive CML; GIST; other BCR-ABL/KIT/PDGFR-driven malignancies | Enquire |
| 49 | ErlotinibOral | Erlotinib | 100, 150 mg | Coated tablets × 30 | EGFR-mutated non-small-cell lung cancer; pancreatic cancer in combination | Enquire |
| 50 | IbrutinibOral | Ibrutinib | 140 mg | Hard capsules × 90 / × 120 | CLL/SLL; Waldenström macroglobulinemia; selected B-cell lymphomas | Enquire |
| 51 | PemetrexedInjectable | Pemetrexed | 500 mg | Lyophilized for injection; vial × 1 | Non-small-cell lung cancer; malignant pleural mesothelioma | Enquire |
| 52 | LenvatinibOral | Lenvatinib | 4, 10 mg | Hard capsules × 30 | Differentiated thyroid cancer; renal cell carcinoma; hepatocellular carcinoma; endometrial cancer in combinations | Enquire |
| 53 | CarfilzomibInjectable | Carfilzomib | 60 mg* | Lyophilized for injection; vial × 1 | Relapsed/refractory multiple myeloma | Enquire |
| 54 | PonatinibOral | Ponatinib | 15–45 mg | Coated tablets × 30 / × 60 | Philadelphia chromosome-positive CML; Ph+ ALL, including T315I mutation | Enquire |
| 55 | CyclophosphamideInjectable | Cyclophosphamide | 200 mg | Lyophilized for injection; vial × 5 | Lymphomas; leukemias; breast and ovarian cancers; conditioning regimens | Enquire |
| 56 | CisplatinInjectable | Cisplatin | 10–50 mg | Solution for injection; vial × 1 | Testicular, ovarian, bladder, lung, head and neck and other solid tumors | Enquire |
| 57 | DecitabineInjectable | Decitabine | 50 mg* | Lyophilized for injection; vial × 1 | Myelodysplastic syndromes; acute myeloid leukemia | Enquire |
| 58 | DexrazoxaneInjectable | Dexrazoxane | 500 mg | Lyophilized for injection; vial × 1 | Cardioprotection associated with anthracycline therapy; anthracycline extravasation management in selected settings | Enquire |
| 59 | IrinotecanInjectable | Irinotecan | 20 mg/mL* | Solution for injection; vial × 1 | Metastatic colorectal cancer; other solid tumors in combination regimens | Enquire |
| 60 | Trifluridine/TipiracilOral | Trifluridine/Tipiracil | 15/6.14 mg; 20/8.19 mg | Coated tablets × 30 / × 60 | Metastatic colorectal cancer; metastatic gastric or gastroesophageal-junction cancer | Enquire |
No products match your search. Ask us about a product — our range is growing.
This list is provided for healthcare professionals and institutional buyers for information only. Strengths, pack sizes and indications are indicative and may vary by market. Availability in Pakistan is subject to DRAP registration, licensing and supply arrangements — please contact us to confirm.
Enquire about a product
Send us the product, strength and quantity you need and we will confirm availability and supply options.